Podcasts about Surgical oncology

In today's episode, we sat down for part 2 of our discussion with Elizabeth Mittendorf, MD, PhD, MHCM, the 2026-2027 president-elect of the American Society of Clinical Oncology (ASCO). Dr Mittendorf holds numerous leadership roles, including the Robert and Karen Hale Distinguished Chair in Surgical Oncology and vice chair for research in the Department of Surgery at Brigham and Women's Hospital; co-leader of the Breast Program and director of the Breast Immuno-Oncology Program at the Dana-Farber Brigham Cancer Center; co-leader of the Parker Institute for Cancer Immunotherapy at the Dana-Farber Cancer Institute; and a professor of surgery at Harvard Medical School, all in Boston, Massachusetts. In this discussion, Dr Mittendorf shared how ASCO is strategically preparing to address the long-term implications of proposed federal research funding cuts. She emphasized the significant return on investment generated by sustained NIH support, underscoring its role in fostering scientific innovation and stimulating the broader economy. She also advocated for structural reforms to be developed collaboratively with researchers, institutions, and policymakers to ensure continued progress in oncology is maintained, particularly in underfunded areas, such as prevention research. Dr Mittendorf also previewed her broader vision for ASCO, including expanding global collaboration and advancing equitable access to cancer care. She noted that these efforts will be complemented by continued emphasis on multidisciplinary care delivery and mentorship, which she discussed in more detail in part one of our conversation.

In today's episode, we had the pleasure of speaking with Elizabeth Mittendorf, MD, PhD, MHCM, the 2026 president-elect of ASCO. Dr Mittendorf is the Robert and Karen Hale Distinguished Chair in Surgical Oncology and the vice chair for research in the Department of Surgery at the Brigham and Women's Hospital; co-leader of the Breast Program and director of the Breast Immuno-Oncology Program at the Dana-Farber Brigham Cancer Center; co-leader of the Parker Institute for Cancer Immunotherapy at the Dana-Farber Cancer Institute; and a professor of surgery at Harvard Medical School, all in Boston, Massachusetts.  In our exclusive interview, Dr Mittendorf discussed her priorities for advancing oncology practice and improving patient outcomes during her presidency. These include multidisciplinary cancer care, workforce well-being, leveraging artificial intelligence to enhance efficiency, and addressing global cancer care. She also emphasized the importance of mentorship and sponsorship for early career professionals, highlighting her personal experience with multiple mentors and her commitment to supporting the next generation of oncology professionals. 

कॅन्सर म्हंटल की सामान्य माणसाला धडकी भरते, पण कॅन्सरला आता आपण खरंच घाबरलं पाहिजे का? डॉ. राज नगरकर यांनी आजच्या एपिसोड मध्ये कॅन्सर बद्दलचे गैरसमज उलगडून सांगितले आहेत! कॅन्सर कडे आणि कॅन्सर पेशंट कडे बघण्याचा आपला दृष्टिकोन कसा असला पाहिजे? कॅन्सर ची नेमकी कारणं काय आहेत? कॅन्सर पूर्णपणे बरा होऊ शकत नाही का? कॅन्सरच्या भीतीला आपण कश्या पद्धतीने सामोरे जाऊ शकतो? भारतात कॅन्सरवरील उपचारासाठी कोणते पर्याय उपलब्ध आहेत? या सगळ्यावर आपण खुसपुस केली आहे; पूर्ण एपिसोड नक्की बघा.When we hear the word "canc*r," it often strikes fear in the hearts of many. But do we really need to be so afraid of canc*r today? In this episode, Dr. Raj Nagarkar helps dispel some of the most common myths surrounding canc*r.How should we perceive cancer and those who are battling it? What exactly causes canc*r? Is it true that canc*r can never be completely cured? How can we face the fear associated with this disease? What treatment options are currently available in India for canc*r patients?We've explored all these questions and more in today's insightful conversation. Don't miss the full episode!आणि मित्रांनो आपलं Merch घेण्यासाठी लगेच click करा! Amuktamuk.swiftindi.comDisclaimer: व्हिडिओमध्ये किंवा आमच्या कोणत्याही चॅनेलवर पॅनलिस्ट/अतिथी/होस्टद्वारे सांगण्यात आलेली कोणतीही माहिती केवळ general information साठी आहे. पॉडकास्ट दरम्यान किंवा त्यासंबंधात व्यक्त केलेली कोणतीही मते निर्माते/कंपनी/चॅनल किंवा त्यांच्या कोणत्याही कर्मचाऱ्यांची मते/अभिव्यक्ती/विचार दर्शवत नाहीत.अतिथींनी केलेली विधाने सद्भावनेने आणि चांगल्या हेतूने केलेली आहेत ती विश्वास ठेवण्याजोगी आहेत किंवा ती सत्य आणि वस्तुस्थितीनुसार सत्य मानण्याचे कारण आहे. चॅनलने सादर केलेला सध्याचा व्हिडिओ केवळ माहिती आणि मनोरंजनाच्या उद्देशाने आहे आणि चॅनल त्याची अचूकता आणि वैधता यासाठी कोणतीही जबाबदारी घेत नाही.अतिथींनी किंवा पॉडकास्ट दरम्यान व्यक्त केलेली कोणतीही माहिती किंवा विचार व्यक्ती/कास्ट/समुदाय/वंश/धर्म यांच्या भावना दुखावण्याचा किंवा कोणत्याही संस्था/राजकीय पक्ष/राजकारणी/नेत्याचा, जिवंत किंवा मृत यांचा अपमान करण्याचा हेतू नाही.. Guest: Prof. Dr. Raj Nagarkar Managing Director and Chief of Surgical Oncology & Robotic Services, Manavata Health Campus, Nashik.Host: Omkar Jadhav.Creative Producer: Shardul Kadam.Editors: Rohit Landge.Edit Assistant: Rameshwar Garkal, Ranjit Kasar.Content Manager: Sohan Mane.Social Media Manager: Sonali Gokhale.Legal Advisor: Savani Vaze.Business Development Executive: Sai Kher.Intern: Mrunal Arve.About The Host Omkar Jadhav.Co-founder – Amuk Tamuk Podcast NetworkPodcast Host | Writer | Director | Actor | YouTube & Podcast ConsultantWith 8+ years in digital content, former Content & Programming Head at BhaDiPa & Vishay Khol.Directed 100+ sketches, 3 web series & non-fiction shows including Aai & Me, Jhoom, 9 to 5, Oddvata.Creative Producer – BErojgaar | Asst. Director – The Kerala StoryHost of Khuspus – a podcast on taboo and uncomfortable topics.Visiting Faculty – Ranade Institute, Pune University.Connect with us: Twitter:   / amuk_tamuk  Instagram:   / amuktamuk  Facebook:   / amuktamukpodcasts  Spotify: Khuspus #AmukTamuk #MarathiPodcasts

Dr. Alipi Bonm, a neuro-oncologist at the Providence Swedish Cancer Institute in Seattle, joins host Dr. Ashwani Rajput to offer up valuable insights into brain cancer, from what to expect to the promising treatment options available that could ease your fears. He also debunks common myths, such as the misconception that cell phones and electrical wires cause brain cancer and highlights promising future treatments. If you or a loved one are affected by brain cancer, discover the support groups available for both patients and caregivers. Don't miss out on this informative and supportive discussion.Dr. Ashwani Rajput BioSee below Do you want to know more?Check out the Providence blog for more information on melanoma and other cancer related topics. Personalized cancer peptide vaccine shows remarkable promise against glioblastomaProvidence Saint John's opens last phase of clinical trial of promising drug for aggressive brain cancerTo learn more about our mission programs and services, go to Providence.org.Follow us on social media to get continued information on other important health care topics. You can  connect with us on LinkedIn, Facebook, TikTok, Instagram and X.For all your healthcare information on the go, download the Providence app. Whether you're tracking symptoms, scheduling appointments, or connecting with your healthcare providers, the Providence app has your back.To learn more about the app, check out the Wellness Brief podcast episode. Wellness Brief: Simplifying Care-There's an App for That.We'd love to hear from you. You can contact us at FutureOfHealthPodcasts@providence.org Dr. Ashwani Rajput BioAshwani Rajput, MD, FACS, joined Providence Swedish in September 2024 as the regional executive medical director (EMD) of the Swedish Cancer Institute. Dr. Rajput comes to us from Johns Hopkins University, where he is a professor of Surgery and Oncology, as well as the director of the Hopkins Kimmel Cancer Center in the Washington, D.C. region. Dr. Rajput completed his medical school, general surgery training, and a post-doctoral fellowship in molecular genetics at Case Western Reserve University in Cleveland, Ohio. He went on to the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., for a fellowship in Complex General Surgical Oncology (CGSO). There, he was recruited to join the faculty at Roswell Park with appointments in GI Surgical Oncology as well as Pharmacology and Therapeutics. His laboratory investigated the key signal transduction pathways in colorectal metastases using novel orthotopic murine models. In 2009, Dr. Rajput was recruited to the University of New Mexico as the inaugural division chief of Surgical Oncology. During his tenure in New Mexico, he also served as the director of surgical services for the NCI-designated Comprehensive Cancer Center and vice-chair of surgery for academic affairs and faculty development. Under his leadership, an ACGME-approved fellowship in CGSO was created and launched. Throughout his roles in New Mexico and D.C., he has actively addressed cancer health care outcomes and health equity. Under Dr. Rajput's leadership, he will develop and implement a cancer strategic vision and enhance collaboration across our geography. He will oversee the SCI medical directors and partner with the Senior Director of Operations to deliver excellence in cancer care. Dr. Rajput and his wife, Sunita, have four children. Outside of work, he enjoys playing tennis, piano, the arts, and traveling.

Dr. Jennifer Wargo is an Associate Professor in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center and a Stand Up To Cancer researcher. Jennifer is a physician scientist, and this means she splits her time between providing care to patients and doing research to find better ways of treating disease. Specifically, Jennifer performs surgeries and treats patients one day each week. She spends the rest of her week studying how to better treat patients with cancer and how cancer may ultimately be prevented. When she's not doing research or treating patients, Jennifer enjoys spending quality time with her family. Some of their favorite activities include going for walks, biking, hiking, and visiting the beach. Jennifer also likes to explore her creative side through art and photography, as well as to be active through running, biking, yoga, and surfing. She received her A.S. degree in nursing and B.S. degree in biology from Gwynedd-Mercy College. Afterwards, Jennifer attended the Medical College of Pennsylvania where she earned her M.D. Jennifer completed her Clinical Internship and Residency in General Surgery at Massachusetts General Hospital. Next, Jennifer was a Research Fellow in Surgical Oncology at the University of California, Los Angeles. She then accepted a Clinical Residency in General Surgery at Massachusetts General Hospital. From 2006-2008, Jennifer was a Clinical Fellow in Surgical Oncology at the National Cancer Institute of the National Institutes of Health. She then served on the faculty at Massachusetts General Hospital and Harvard University. In 2012, Jennifer received her MMSc. degree in Medical Science from Harvard University. Jennifer joined the faculty at The University of Texas MD Anderson Cancer Center in 2013. She is Board Certified by the American Board of Surgery, and she has received numerous awards and honors throughout her career. These have included the R. Lee Clark Prize and Best Boss Award from the MD Anderson Cancer Center, the Rising STARS and The Regents' Health Research Scholars Awards from the University of Texas System, the Outstanding Young Investigator and Outstanding Investigator Awards from the Society for Melanoma Research, as well as a Stand Up To Cancer Innovative Research Grant for her microbiome work. She has also received other awards for excellence in teaching, research, and patient care. In our interview, Jennifer shares more about her life and science.

Join us for the inaugural episode of "TWAD: Cancer, Cures and Coffee" with Dr. Ashwani Rajput and special guest Dr. Kelly Paulson. In this episode, we dive deep into the topic of Melanoma, one of the most serious types of skin cancer. Dr. Paulson, a medical oncologist at Swedish Cancer Institute First Hill in Seattle, shares her expertise on the importance of early detection, risk factors, and the latest advancements in treatment. Learn how to protect yourself and your loved ones from Melanoma and discover the role of the immune system in fighting cancer. Don't miss this informative and engaging discussion.Dr. Ashwani Rajput BioSee below Do you want to know more?Check out the Providence blog for more information on melanoma and other cancer related topics. ·       Cancer survivor speaks with doctor he credits for saving his life·       Saint Patrick HealthBreak - Skin Cancers·       A year to remember: Advancements, recognition and transitions To learn more about our mission programs and services, go to Providence.org.Follow us on social media to get continued information on other important health care topics. You can  connect with us on LinkedIn, Facebook, TikTok, Instagram and X.For all your healthcare information on the go, download the Providence app. Whether you're tracking symptoms, scheduling appointments, or connecting with your healthcare providers, the Providence app has your back.To learn more about the app, check out the Wellness Brief podcast episode. Wellness Brief: Simplifying Care-There's an App for That. We'd love to hear from you. You can contact us at FutureOfHealthPodcasts@providence.org Dr. Ashwani Rajput BioAshwani Rajput, MD, FACS, joined Providence Swedish in September 2024 as the regional executive medical director (EMD) of the Swedish Cancer Institute. Dr. Rajput comes to us from Johns Hopkins University, where he is a professor of Surgery and Oncology, as well as the director of the Hopkins Kimmel Cancer Center in the Washington, D.C. region. Dr. Rajput completed his medical school, general surgery training, and a post-doctoral fellowship in molecular genetics at Case Western Reserve University in Cleveland, Ohio. He went on to the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., for a fellowship in Complex General Surgical Oncology (CGSO). There, he was recruited to join the faculty at Roswell Park with appointments in GI Surgical Oncology as well as Pharmacology and Therapeutics. His laboratory investigated the key signal transduction pathways in colorectal metastases using novel orthotopic murine models. In 2009, Dr. Rajput was recruited to the University of New Mexico as the inaugural division chief of Surgical Oncology. During his tenure in New Mexico, he also served as the director of surgical services for the NCI-designated Comprehensive Cancer Center and vice-chair of surgery for academic affairs and faculty development. Under his leadership, an ACGME-approved fellowship in CGSO was created and launched. Throughout his roles in New Mexico and D.C., he has actively addressed cancer health care outcomes and health equity. Under Dr. Rajput's leadership, he will develop and implement a cancer strategic vision and enhance collaboration across our geography. He will oversee the SCI medical directors and partner with the Senior Director of Operations to deliver excellence in cancer care. Dr. Rajput and his wife, Sunita, have four children. Outside of work, he enjoys playing tennis, piano, the arts, and traveling.

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the May 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Min Deng, MD, and Erica Leavitt, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the May issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net. 

This interview with Walter Lawrence Jr. was conducted in 2020, when Lawrence was 95 years old and director emeritus of VCU Massey Cancer Center. Lawrence died one year later, on Nov. 9, 2021.Lawrence was one of the founders of the field of surgical oncology, setting up the first-ever university-based division of surgical oncology at what later became VCU Massey Comprehensive Cancer Center, in Richmond, Virginia. He served as director of VCU Massey from 1975 to 1988, during which time the cancer center earned NCI designation.Lawrence spoke with Paul Goldberg, editor and publisher of The Cancer Letter, and Robert Winn, director of VCU. “The thing that was exciting about the National Cancer Act, which I think was one of the best things President Nixon did, among things that weren't so good, was that it did bring the federal government into the funding of various kinds of research,” Lawrence said.Lawrence saw promise in the National Cancer Act, and earning the Cancer Center designation from NCI in 1975 allowed VCU, then called the Medical College of Virginia, to become systematically involved in clinical trials.“Randomized clinical trials were the only way we had of really improving patient cancer care—things like the one that Bernie Fisher in Pittsburgh started, the National Surgical Adjuvant Breast and Bowel Project,” Lawrence said.Read more and explore related archives at https://cancerhistoryproject.com/article/walter-lawrence-podcast/

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the April 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Desiree Ratner, MD, and Shayna Rivard, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the April issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

Dr. Michael R. Markiewicz, Surgical Oncology and Reconstruction Section Editor for the Journal of Oral and Maxillofacial Surgery, joins the podcast to discuss innovative research published in the Journal and what it means for the future of the specialty.

“Can they even call it that anymore?” Yes, we can because diversity is not a dirty word. It represents a healthy ecosystem. Diversity is better for forests, microbiomes, ocean-dwelling species, T cell function, and yes the workforce. Join Susanne G. Warner, MD and LaDonna Kearse, MD for a conversation with three phenomenal surgical oncologists and leaders — Callisia Clarke, MD, MS, FACS, FSSO, John H. Stewart IV, MD, MBA, FACS, and Sarah Shubeck, MD — as they explore how to build teams that synergize toward maximized potential, how to navigate the discomfort of actual change, and how to be about it when not everyone will talk about it.

The International Career Development Exchange (ICDE) program provides support for up-and-coming, early career surgical oncologists with leadership potential to receive one-on-one mentoring and engagement with a distinguished senior SSO member. SSO supports a participant from each of our 15 Global Partner Societies, plus two SSO member participants from countries not connected to one of our Global Partners. Participants receive complimentary registration for the SSO annual meeting and the opportunity to participate in a minimum one-week clinical observership at a US-based SSO member's institution. Each participant is paired with an SSO Member Mentor with the goal that a long-term professional relationship will develop and continue over the course of the participant's career. In this episode past ICDE recipients are interviewed about their experiences and the impact of the ICDE program on their career trajectories.

In today's episode, Dr. Mitchell Posner, Dr. Sarah Shubeck, and Dr. Jelani Williams on the University of Chicago Medicine's new Comprehensive Cancer Center. Scheduled to open in 2027, the new center is a seven-floor, 575,000-square-foot building planned to have 80 private beds and 90 consultation and outpatient rooms. At the moment, the center is anticipated to see 200,000 outpatient visits and 5000 inpatient admissions annually. This would be the city of Chicago's first freestanding cancer pavilion.How will we ensure that this new center prioritizes the community's needs? In Chicago's South Side, cancer death rates are twice the national average, and cancer is also the second-leading cause of death on the South Side behind heart disease. In this conversation, you'll hear about the center's development, what patients can expect, and most importantly, the Department of Surgery's commitment to ensure the cancer center supports those who are most vulnerable. Dr. Mitchell Posner is the Thomas D. Jones Distinguished Service Professor of Surgery, Chief of the Section of General Surgery, and the Chief Clinical Officer of the University of Chicago Medicine Comprehensive Cancer Center. From clinical trials for cancer treatment to his more than 250 articles, abstracts, and book chapters, Dr. Posner is a leading authority in the management of upper gastrointestinal cancers. He is frequently voted among the country's best doctors. He is the past president of the Society of Surgical Oncology. He is deputy editor of the Annals of Surgical Oncology and section editor for the gastrointestinal cancer section of the journal Cancer. He served as chairman of the Gastrointestinal Committee of the American College of Surgeons Oncology Group (ACOSOG).Dr. Sarah Shubeck is an Assistant Professor in the Department of General Surgery. She is a Breast Surgical oncologist specializing in breast surgery, cancer, and benign disease treatment. In addition to her clinical practice, Dr. Shubeck's research has been published in many journals including Cancer, JAMA Surgery, and Annals of Surgical Oncology.Dr. Jelani Williams is a 5th-year general surgery resident at the University of Chicago. He is an aspiring surgical oncologist and attended the Eastern Virginia Medical School. He has published research on predictive models and surgery for metastatic pancreatic neuroendocrine tumors as well as the use of machine learning to distinguish benign and malignant thyroid nodules amongst other topics. Deep Cuts: Exploring Equity in Surgery comes to you from the Department of Surgery at the University of Chicago, which is located on Ojibwe, Odawa and Potawatomi land.Our executive producer is Tony Liu. Our senior producers are Alia Abiad, Caroline Montag, and Chuka Onuh. Our production team includes Megan Teramoto, Ria Sood, Ishaan Kumar, and Daniel Correa Bucio. Our senior editor and production coordinator is Nihar Rama. Our editorial team also includes Beryl Zhou and Julianna Kenny-Serrano. The intro song you hear at the beginning of our show is “Love, Money Part 2” from Chicago's own Sen Morimoto off of Sooper Records. Our cover art is from Leia Chen.A special thanks this week to Dr. Jeffrey Matthews — for his leadership, vision, and commitment to caring for the most vulnerable in our communities. Let us know — what have you most enjoyed about our podcast. Where do you see room for improvement? You can reach out to us on Instagram @deepcutssurgery. Find out more about our work at deepcuts.surgery.uchicago.edu.

In this episode of SurgOnc Today, Laura Dominici, MD is joined by Laura Rosenberger, MD and David Anderson, MD, to discuss the current strategies around diagnosis and management of phyllodes tumors.

Appendiceal neoplasms present with peritoneal carcinomatosis and despite aggressive CRS/HIPEC, often recur and are chemotherapy resistant. In this Colorectal DSWG SSO sponsored podcast episode, we discuss an overview of the recent publication of "Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis with GNAS Mutations" by Dr. Lowy's research lab at UCSD. The authors treated 16 patients in this Phase 2 study of oral Palbociclib in recurrent appendiceal adenocarcinoma patients and identified excellent treatment and long-term response with 13/16 of patients treated having reduction in CEA and excellent survival (median FU of 17.6 months, OS not reached). Dr Lowy provides informative background, study details and discusses next steps for this novel treatment approach. A link to the paper in question is https://pubmed.ncbi.nlm.nih.gov/39413348/

In this episode of SurgOnc Today, Dr. Julie Hallet and Dr. Patricio Polanco, Chair and Vice-Chair of the SSO HPB Disease Site Working Group review key updates and takeaways from the recent AHPBA Annual Meeting held in March 2025 in Miami. They are joined by Dr. Ryan Ellis and Dr. Michael Lidsky to review clinical trials on locally advanced pancreas cancer, hepatic artery infusion pump, colorectal liver metastases, and pancreas neuroendocrine tumors.

In this episode of SurgOnc Today, Dr. Julie Hallet, chair of the HPB disease site working group, and Dr. Callisia Clarke, member of the SSO board of directors, are joined by Dr. Jessica Maxwell and Dr. Alexandra Gangi to explore the evolving field of surgery for neuroendocrine tumors liver metastases. They discuss patient selection, pre-operative optimization, and unique surgical techniques to optimize perioperative and oncologic outcomes.

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Evan Glazer, MD, a colleague at Regional One Health in Memphis, TN, part of the University of Tennessee Health Science (UTHSC) system. Dr. Glazer is a practicing surgical oncologist and Associate Professor of Surgery at UTHSC. He also received Memphis Magazine's 2024 Innovator Award. During our 25-minute conversation, Dr. Glazer described the extensive training that led to his current position as a surgical oncologist at Regional One Health. He completed four years of college, four years of medical school, five years of general surgery residency, two years of a research fellowship on liver and pancreas cancer, and then two years of clinical fellowship at the Moffit Cancer Center, Tampa, FL, a total of 17 years of training! Dr. Glazer is now a Board-Certified Surgical Oncologist. Dr. Glazer explained that in the US, general surgeons provide most surgical cancer care. However, some cases are complex and require additional skills, which is where a surgical oncologist can step in. Surgical oncologists routinely operate on cancer patients, which gives them a level of experience and expertise not always possessed by general surgeons.  Dr. Glazer explained how advances in neuroimaging, including CT, MRI, and PET scans, have aided surgeons by better identifying anatomical structures that vary from patient to patient. Collaboration between medical oncologists, surgical oncologists, radiologists, radiation oncologists, pathologists, and others can lead to optimal clinical results. Cancer is not always a "death sentence" as it used to be. To learn more, please watch on YouTube or listen on your favorite streaming device! To contact Dr. Glazer, please call Regional One Health: 901.545.7100.Please click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

Dr. Deepa Magge invited Dr. Belain Eyob and Dr. Kimberly Kopecky to discuss highlights from the 2025 ACT meeting in Scottsdale, Arizona. The guests discuss the three major portions of the ACT 2025 conference, including the HPB section, the PSM component, as well as the melanoma and other regional therapies portion.

Listen to the final episode of this 4-part Women in Cancer Surgery podcast series on finance hosted through SurgOnc Today®. In this episode, Dr. Melissa Hogg, a member of the Women in Cancer Surgery Committee, and Dr. Tari King, Chief of Breast Surgery at Dana-Farber Brigham Cancer Center discuss organizational fund flow and share insights on managing financial matters in the field.

In this episode of SurgOnc Today®, Dr. Patricio Polanco, from the University of Texas Southwestern and Vice-chair of the SSO HPB disease site working group, and Dr. Sandra DiBrito, from Albany Medical College and member of the HPB disease site working group, are joined by Dr. Marc Besselink, of Amsterdam University Medical Center, and Dr. Amer Zureikat, of University of Pittsburgh. This is the second episode in our Minimally Invasive Techniques in Hepatobiliary Surgery Series. We will focus today on minimally invasive pancreas surgery.

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the March 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Sherrif F. Ibrahim, MD, PhD, and Jordan Lim, MB, BCh, BAO. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the March issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

In this episode of SurgOnc Today®, Dr. Patricio Polanco from the University of Texas Southwestern and Vice-chair of the SSO HPB disease site working group and Dr. Sandra DiBrito from Albany Medical College and member of the HPB disease site working group are joined by Dr. Asmund Fretland of the University of Oslo and Dr. Laleh Melstrom of City of Hope. This is the first episode in our Minimally Invasive Techniques in Hepatobiliary Surgery Series. We will focus on the minimally invasive surgery techniques on the liver, discussing patient selection, benefits of the MIS approach, potential drawbacks, and the impact of this approach on patient outcomes.

Medical, surgical, radiation, and interventional oncology all play vital roles in delivering care to patients battling liver cancer. How do we optimize outcomes when so many specialties have something to offer the same patient? The answer is collaborative oncology. Dr. Robert Martin (Director of Surgical Oncology, University of Louisville) and pioneer in liver-directed therapies, joins host Dr. Sabeen Dhand to discuss a collaborative approach to oncology and recent advances in locoregional therapy. --- This podcast is supported by: RADPAD® Radiation Protection https://www.radpad.com/ --- SYNPOSIS Dr. Martin discusses the importance of a growth mindset in advancing medical techniques and fostering collaborations between specialists. He then shares insights into minimally invasive procedures, such as microwave ablation and irreversible electroporation (IRE). The doctors also touch on the evolution of liver cancer treatments, emphasizing the significance of clinical trials on the horizon. To conclude, Dr. Martin encourages young professionals in surgery and interventional radiology to stay open-minded, be life-long learners, and find synergistic ways to integrate new technologies into patient care. --- TIMESTAMPS 00:00 - Introduction 02:31 - Dr. Martin's Background and Career Path 06:18 - Evolution of Liver Directed Therapies 10:12 - Collaboration Between Specialties 18:34 - Clinical Trials and Emerging Therapies 36:08 - Advice for Young Professionals 39:15 - Conclusion --- RESOURCES Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of HCC: https://clinicaltrials.gov/study/NCT05953337?term=NCT05953337&rank=1 Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1): https://clinicaltrials.gov/study/NCT05688280 Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3: https://immunophotonics.com/news/immunophotonics-cirse-and-next-research-announce-innovative-phase-2-3-clinical-trial-injectabl-3/

Speaking of SurgOnc® has a new home! New episodes can now be found under the Society of Surgical Oncology's podcast, SurgOnc Today®, available on all major podcast platforms. Subscribe today to receive updates on new episode releases.  In this new episode of Speaking of SurgOnc®, Dr. Rick Greene discusses with Dr. Jeffrey Velotta the hypothesis that additional D2 dissection in Siewert II gastroesophageal junction cancer does not lead to increased survival and may not need to be routinely performed, as reported in their article, "The Impact of D2 Versus D1 Lymphadenectomy in Siewert II Gastroesophageal Junction (GEJ) Cancer."

Native Americans are located throughout the United States in both urban and rural environments. In this episode of SurgOnc Today®, Drs. Michelle Huyser, Jennifer Erdrich, and Vanessa Jensen discuss challenges and unique aspects of providing Native American Cancer Care to this population from both an academic as well as community perspective.

In the second episode of a two-part series on surgical oncology, host Rick Greene, MD, FACS, is once again joined by Drs. John Stewart and Prakash Pendalai to discuss the important features of head and neck malignancies, benign and malignant gynecologic conditions, and principles of palliative care for patients with cancer. Learn more about Selected Readings in General Surgery, an American College of Surgeons publication that highlights highly relevant and practice-changing information from the world's most prominent medical journals. #SurgicalReadings #SRGS

In this episode of SurgOnc Today®, the Breast DSWG and the Community Practice Surgeons Committee examine emerging technologies in the ablative setting for patients with breast cancer.

Join us for Part 1 of this 4-part Women in Cancer Surgery podcast series on finance hosted through SurgOnc Today. In this episode, Chair of the Women in Cancer Surgery Committee, Dr. Sarah McLaughlin, and Committee Member, Dr. Aimee Crago, will be joined by Alice Rigdon, Chief Financial Officer at the Mayo Clinic in Florida to provide a primer on financial literacy as it relates to department, division, and institutional finances. It will provide a broad framework of common terms and associated financial definitions.

GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. Today I am joined by friend and colleague, Dr. Matthew Lederman, and we discuss the cancer treatment that has been offered and just approved my insurance company. A final decision will be made very soon. Dr. Lederman also discusses how cancer grows and doubles, when treatment works, why and when it doesn't. Here are the articles in the medical journals he referred to today: Journal of Surgical Oncology 1997;65:284–297 https://pubmed.ncbi.nlm.nih.gov/9274795/ https://pubmed.ncbi.nlm.nih.gov/19843904/ https://pubmed.ncbi.nlm.nih.gov/15630849/ To book a session with Dr. Lederman: http://connectionDocs.com ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 Dr. Lederman is the co-host of the webe Parents podcast, a platform dedicated to equipping parents with tools and insights to foster emotional connection, resilience, and well-being in their families. His latest book, Wellness to Wonderful, weaves together medical science, psychology, spirituality, and life wisdom to guide individuals toward lasting health, vibrancy, peace, and joy. He has co-authored six books, including the New York Times Bestseller Forks Over Knives Plan, and was featured in the acclaimed documentary Forks Over Knives. Through these works, he has shared his transformative approach to wellness with audiences around the globe. In addition to his roles as a clinician, educator, speaker, and corporate advisor, Dr. Lederman has served as Vice President of Medical Affairs at Whole Foods Market, lectured for eCornell, and provided adjunct faculty instruction in medical schools. He also co-created the webe kälm device, designed to promote emotional regulation and soothe the nervous system. As the co-founder of Connection Docs, Dr. Lederman integrates the principles of Nonviolent Communication and emotional health with practical tools to enhance relational and self-connection. Through this groundbreaking platform, he continues to empower individuals and families to strengthen their emotional well-being and build meaningful relationships. Website: http://connectionDocs.com

You're a new attending leading a busy surgical service. You're tasked with teaching a team that includes every learner from medical students to junior and senior residents—all from different generations. How do you adapt your teaching style to effectively reach everyone? Dr. Abbey Fingeret, Endocrine Surgeon at University of Nebraska and passionate Surgical Educator, joins our host, Dr. Elizabeth Maginot, to explore strategies for engaging learners across generations and creating inclusive, dynamic teaching environments. Hosts: Dr. Abbey Fingeret, MD, MHPTT, FACS: Associate Professor, University of Nebraska Medical Center Department of Surgery, Division of Surgical Oncology, Twitter: @DrFingeret Dr. Elizabeth Maginot, MD: General Surgery Resident and BTK Surgical Education Fellow, University of Nebraska Medical Center, Twitter: @e_magination95 Learning Objectives: -  Understand the defining characteristics of Baby Boomers, Gen X, Millennials, and Gen Z, and how these traits influence their learning and teaching styles in medical education. -  Explore how to adapt teaching strategies for multigenerational learners by understanding and addressing their unique perceptions of education, feedback, and expectations in the clinical setting. -  Discuss methods to build a positive learning environment that fosters collaboration and inclusivity across all levels of trainees. -  Recognize the strengths and challenges different generations bring to medical education and how to leverage these to enhance team learning and patient care." References  Stillman, D., & Stillman, J. (2017). Gen Z@ work: How the next generation is transforming the workplace. HarperCollins. https://pubmed.ncbi.nlm.nih.gov/?term=Stillman%2C+D.%2C+%26+Stillman%2C+J.+%282017%29.+Gen+Z%40+work%3A+How+the+next+generation+is+transforming+the+workplace.+HarperCollins. Elmore, T., & McPeak, A. (2019). Generation Z unfiltered: Facing nine hidden challenges of the most anxious population. Poet Gardener Publishing. Twenge, J. M. (2023). Generations: The Real Differences Between Gen Z, Millennials, Gen X, Boomers, and Silents—and What They Mean for America's Future. Simon and Schuster. ***SPECIALTY TEAM APPLICATION LINK: https://docs.google.com/forms/d/e/1FAIpQLSdX2a_zsiyaz-NwxKuUUa5cUFolWhOw3945ZRFoRcJR1wjZ4w/viewform?usp=sharing Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.

In this episode of SurgOnc Today®, Dr. Rebecca Snyder, from the UT MD Anderson Cancer Center, and Dr. Akhil Chawla, from Northwestern University, both members of the HPB disease site working group, are joined by Dr. Cristina Ferrone, from Cedars Sinai Medical Center, and Dr. Steven Gallinger, from the University of Toronto. We will discuss the details, similarities, and differences of their respective clinical trials for neoadjuvant therapy for pancreatic adenocarcinoma, ALLIANCE A021806, and NeoPancONE.   References/Resources: ALLIANCE A021806 NeoPancONE

Join the Behind the Knife Surgical Oncology Team as we discuss the presentation, work-up, and management of neuroendocrine tumors of the small bowel. Learning Objectives: In this episode, we review the basics of neuroendocrine (NE) tumors of the small bowel, including how to evaluate patients with presenting symptoms consistent with NE tumors, initial work-up, staging, and management.  We discuss key concepts including DOTATATE scans and medical therapies high yield for direct patient care and board exams.  Hosts: Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist/HPB surgeon at Kaiser LAMC in Los Angeles. Connor Chick, MD (@connor_chick) is a 2nd Year Surgical Oncology fellow at Ohio State University. Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a 1st Year Surgical Oncology fellow at MD Anderson. Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a PGY-6 General Surgery resident at Brooke Army Medical Center Links to Paper Referenced in this Episode: Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. PMID: 28076709; PMCID: PMC5895095. https://pubmed.ncbi.nlm.nih.gov/28076709/ ***SPECIALTY TEAM APPLICATION LINK: https://docs.google.com/forms/d/e/1FAIpQLSdX2a_zsiyaz-NwxKuUUa5cUFolWhOw3945ZRFoRcJR1wjZ4w/viewform?usp=sharing Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.

In this episode of SurgOnc Today®, Micah Brainerd, MD, is joined by Dr. Mediget Teshome, MD, MPH, Dr. Ronald P. DeMatteo, MD, FSSO, and Dr. Anthony Visioni, MD, reflecting on their journeys to their current leadership position, and the advice they would give their younger selves as they navigated the process. This is the second of the two-part series where each will discuss their ways of managing the demanding career of a surgical oncologist with their personal lives.

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the February 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Ramona Beshad,MD, and Deirdre Connolly, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast the cosmetic and general dermatology articles in February issue are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

Speaking of SurgOnc® has a new home! New episodes can now be found under the Society of Surgical Oncology's podcast, SurgOnc Today®, available on all major podcast platforms. Subscribe today to receive updates on new episode releases.  In this new episode of Speaking of SurgOnc®, Dr. Rick Greene discusses with Dr. Mark Truty the prognosis, and response to neoadjuvant chemotherapy, of resected invasive intraductal papillary mucinous cystic neoplasms compared with de novo pancreatic ductal adenocarcinoma, as reported in their article, "Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma."

In this episode of SurgOnc Today®, Micah Brainerd, MD, is joined by Dr. Mediget Teshome, MD, MPH, Dr. Ronald P. DeMatteo, MD, FSSO, and Dr. Anthony Visioni, MD, who reflect on their journeys to their current leadership positions and the advice they would give their younger selves as they navigated the process. This is the first of a two-part series where each will discuss their journey to their current leadership positions and reflect on their professional growth in and out of the operating room.

RUSH MD Anderson Cancer Center offers leading-edge treatments for GI cancers, including targeted therapies, immunotherapy, chemotherapy, and minimally invasive surgical options. Our multidisciplinary team of medical oncologists, gastroenterologists, surgical oncologists, colorectal surgeons and interventional radiologists work together to provide our patients with tailored treatment plans to each patient's specific diagnosis and needs. Audrey Kam, MD, is the director of GI medical oncology at RUSH MD Anderson, as well as the research director of GI medical oncology at RUSH MD Anderson. She specializes in treating gastrointestinal cancers including colorectal, esophageal, gastrointestinal, liver, pancreatic and stomach cancers. Sam Pappas, MD, is the Division Chief of Surgical Oncology at Rush University Medical Center. He specializes in treating upper abdominal cancers, including ones in the esophagus, stomach, pancreas, liver and bile duct. “We love collaborating in immediate proximity to each other within RUSH MD Anderson. This helps to ensure coordinated, multidisciplinary discussions that are patient-focused,” explains Dr. Pappas.

In this episode, Dr. Mark Cripe and I are joined by Dr. Kevin Hughes, the Director of Cancer Genetics at the Hollings Cancer Center and the McKoy Rose, Jr., M.D. Endowed Chair in Surgical Oncology in the College of Medicine at MUSC. Dr Hughes is recognized nationally and internationally for his expertise in breast cancer, breast disease management, genetic testing and the identification and management of patients with hereditary breast cancer risk.  His research focuses on developing tools that make cancer genetic testing simple, safe, and efficient.https://hollingscancercenter.musc.edu/patient-care/genetic-counseling-and-hereditary-cancer/hereditary-cancer-clinichttps://web.musc.edu/inourdnascYou will learn:1.    What is the definition of “High Risk”? 2.    What are some risk factors for high risk? 3.    Discuss the different risk calculators? Will AI replace these models? 4.    How do you counsel woman at high risk?   5.    Understanding many obstacles in seeing and counseling patients (socioeconomic, access to quality care, etc) do you think that we can use AI to help us?6.    How does having a high risk (Hereditary cancer clinic) like the one you have benefit hospital systems? 7.    Million-dollar question? Will AI replace physicians and surgeonsJ? Stay Connected with Dr. Deepa Halaharvi:TikTok: @breastdoctorInstagram: @drdhalaharviTBCP Instagram: @thebreastcancerpodcastWebsite: https://drdeepahalaharvi.com/YouTube: https://www.youtube.com/@deepahalaharvi5917Instagram: @thebreastcancerpodcast

In this episode of SurgOnc Today®, Dr. Olga Kantor discusses with Dr. Chandler Cortina and Dr. Puneet Singh the locoregional highlights of the 2024 San Antonio Breast Cancer Symposium, including the COMET, INSEMA, EUROPA and Alliance 11202 trials.

Dr. Poole joins the show sharing details on how we can raise awareness on cancer treatment in the Omaha area.

In this episode of SurgOnc Today®, Drs. Colleen Kiernan, Heather Wachtel, and Jason Liu review endocrine surgery topics for the oral boards. They discuss three endocrine related, oral board style questions and highlight important aspects of each topic. 

In this episode of SurgOnc Today®, Dr. Sinziana Dumitra discusses the evaluation and management of patients with peritoneal metastases from MSI-high colorectal cancer with Dr. Joshua Leinwand and Dr. Zachary Brown, including the role of HIPEC, immunotherapy, and differences in clinical characteristics and outcomes compared with microsatellite-stable disease.

Among patients with colorectal cancer and synchronous liver metastases, the subgroup with a primary cancer in the rectum is especially challenging. Compared with colon cancer, most patients with stage IV rectal cancer will have locally advanced primary tumors at increased risk for obstructive and/or post-operative complications resulting in delays in systemic therapy. In this episode from the HPB team at Behind the Knife, listen in on the discussion about treatment sequencing for synchronous liver metastasis from rectal cancer Hosts Anish J. Jain MD (@anishjayjain) is a current PGY3 General Surgery Resident at Stanford University and a former T32 Research Fellow at the University of Texas MD Anderson Cancer Center. Timothy E. Newhook MD, FACS (@timnewhook19) is an Assistant Professor within the Department of Surgical Oncology. He is also the associate program director of the HPB fellowship at the University of Texas MD Anderson Cancer Center.  Jean-Nicolas Vauthey MD, FACS (@VautheyMD) is Professor of Surgery and Chief of the HPB Section, as well as the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center. Learning Objectives ·      Develop an understanding of the three treatment sequences for resection of disease in patients with synchronous liver metastasis from a primary rectal cancer (reverse, combined, and classic approach) ·      Develop an understanding of the benefits, risks, and nuances of each of the three treatment sequences ·      Develop an understanding of which patient cases each treatment sequence is ideal for as well as which cases they are not suitable for. Papers Referenced (in the order they were mentioned in the episode): 1)    Conrad C, Vauthey JN, Masayuki O, et al. Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases. Ann Surg Oncol. 2017 Dec;24(13):3857-3864.  https://pubmed.ncbi.nlm.nih.gov/28929463/ 2)    Maki H, Ayabe RI, Nishioka Y, et al. Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer. Ann Surg Oncol. 2023 Sep;30(9):5390-5400. doi: 10.1245/s10434-023-13656-4. Epub 2023 Jun 7. Erratum in: Ann Surg Oncol. 2023 Sep;30(9):5405. https://pubmed.ncbi.nlm.nih.gov/37285096/ Additional Suggested Reading Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006 Jul;93(7):872-8.  https://pubmed.ncbi.nlm.nih.gov/16671066/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Speaking of SurgOnc has a new home! New episodes can now be found under the Society of Surgical Oncology's podcast, SurgOnc Today®, available on all major podcast platforms. Subscribe today to receive updates on new episode releases. In this new episode of the ASO Episode Series of SurgOnc Today® (previously Speaking of SurgOnc), Dr. Rick Greene discusses with Dr. Michael Offin the clinicopathologic characteristics and outcomes of a large prospective cohort of well-differentiated papillary peritoneal mesothelial tumors, as reported in their article, "Clinical Characteristics and Outcomes of Patients with Well-Differentiated Papillary Peritoneal Mesothelial Tumors."

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the January 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors David Carr, MD, MPH, and Alexander Valiga, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast for the January issue, cosmetic and general dermatology articles are featured in separate episodes. Your feedback is encouraged. Please contact communicationstaff@asds.net.

In this episode of SurgOnc Today®, Steve Kwon, MD, and Mike Mavros, MD, are joined by Joo Ha Hwang, MD, and Yanghee Woo, MD, for a discussion of managing patients at high-risk of gastric cancer development at the population-level and at the patient-level. The panel will also discuss nonoperative and operative strategies in managing precancerous gastric lesions and early gastric cancers.

This education episode of SurgOnc Today® features a roundtable discussion with input from surgical oncologists and a surgical oncology APPs on exploring the different ways APPs can contribute to a surgical oncology practice, both in the inpatient and outpatient settings.

In this episode of SurgOnc Today, Dr. Julie Hallet and Dr. Patricio Polanco, Chair and Vice-Chair of the HPB disease site, are joined by Drs. Ryan Ellis from Indiana University Scholl of Medicine and Allison Martin from Duke University. They will wrap the 2024 HPB year with us by reviewing the top HPB surgical oncology published this year. References/Resources: #5 NETTER-2 #4 NEOLUPANET #3 TRANSMET #2 PANDORINA #1 NORPACT

In this episode, we review key components of the landmark MAGIC and FLOT-4 trials that investigated perioperative chemotherapy in the treatment of locally advanced gastric cancer.  We discuss limitations of both trials and the evolving clinical landscape of gastric cancer treatment. Hosts: - Timothy Vreeland, MD, FACS (@vreelant) is an Associate Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist/HPB surgeon at Brooke Army Medical Center. - Daniel Nelson, DO, FACS (@usarmydoc24) is a Surgical Oncologist/HPB surgeon at Kaiser Permanente Los Angeles Medical Center. - Connor Chick, MD (@connor_chick) is a Surgical Oncology Senior Fellow at Ohio State. - Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a Surgical Oncology Junior Fellow at MD Anderson Cancer Center. - Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a PGY-6 General Surgery resident at Brooke Army Medical Center.  Learning Objectives:  1.     Understand background, methodology, results, and interpretation of the MAGIC trial. 2.     Understand background, methodology, results, and interpretation of the FLOT trial. 3.     Be able to discuss the evolution of chemotherapeutic regimens in the treatment of locally advanced gastric cancer and rationale for their use. 4.     Be able to describe key limitations for the above regimens. 5.     Discuss the the evolving clinical landscape for chemotherapy in gastroesophageal junction tumors. Links to Papers Referenced in this Episode: Journal Articles: Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J., Nicolson, M., ... & Chua, Y. J. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine, 355(1), 11-20. https://pubmed.ncbi.nlm.nih.gov/16822992/ Al-Batran, S. E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., ... & Hofheinz, R. D. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet, 393(10184), 1948-1957. https://pubmed.ncbi.nlm.nih.gov/30982686/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen